GHK-Cu: What the Evidence Actually Shows

GHK-Cu is a tiny peptide made of three amino acids (glycine, histidine, and lysine) bound to a copper ion. Your body makes it naturally; it's found in blood plasma, saliva, and urine, and levels decline with age. It was first identified in 1973 by researcher Loren Pickart, whose lab and collaborators have produced much of the published research on it since.

You'll find it in two very different forms: as a cosmetic ingredient in creams and serums, and as an injectable sold through clinics and gray-market sites. The evidence and the legal status are different for each.

The best human data comes from controlled studies of creams applied to the face for 8 to 12 weeks. A 12-week placebo-controlled study in 67 women aged 50 to 59 with sun-damaged skin reported improvements in firmness, laxity, clarity, and fine lines with twice-daily use. Other small studies have reported increases in skin thickness and density.

Lab studies offer a plausible explanation: GHK-Cu appears to encourage skin cells to produce collagen and to regulate the enzymes that break it down.

• Not every trial was positive. A 2006 controlled trial of a copper peptide product on laser-resurfaced skin found no objective improvement in wrinkles or skin quality compared with the control, although patients reported higher satisfaction.
• The studies are small and dated. Most involve dozens of people, not hundreds, and many are decades old. Results from one formulation don't automatically transfer to another, and cosmetic products vary widely in concentration and stability.
• Hair growth claims rest mainly on animal experiments. No large human hair-loss trials exist, and approved treatments like minoxidil have far stronger evidence.
• Wound healing, inflammation, and anti-aging "gene" claims come mostly from cell cultures, animal studies, and computer analyses of gene activity. Those are reasons to study GHK-Cu further, not evidence that it does these things in people.
• Injectable GHK-Cu has essentially no published controlled human trials.

Topical cosmetics containing GHK-Cu are legal to sell as cosmetic ingredients, as long as they aren't marketed with drug claims like treating a disease.

Compounding: The FDA has listed non-injectable forms of GHK-Cu in Category 1 since 2023, which means pharmacies can generally compound them under the agency's interim policy. The injectable form was in Category 2 (significant safety risks) until April 2026, when it was removed after its nomination was withdrawn. Removal didn't authorize compounding it. An FDA advisory committee is scheduled to review GHK-Cu in February 2027. See our Category 1 vs. Category 2 explainer and the FDA status tracker.

Topical GHK-Cu is generally well tolerated in studies, though local irritation and, rarely, allergic contact reactions have been reported. Injectable GHK-Cu from unregulated sources carries the usual gray-market risks: unknown purity, dose, and sterility. Read more in what "research use only" really means.

If you're curious about GHK-Cu, the version with the most evidence behind it is also the most ordinary: a skincare product. Expect modest results, not the dramatic claims you'll see online, and know that well-established skincare ingredients like retinoids have a much deeper evidence base.